off-label / investigational
PT-141 for men: off-label and investigational erectile research
The approval covers only HSDD in premenopausal women. The male and erectile evidence exists, but it is early-phase and investigational — presented here as exactly that.
The short version
PT-141 for men is off-label. The FDA approval is only for HSDD in premenopausal women, so using it in men — most often for erectile difficulties — is outside that approval [3][6]. There is real early research: the original pharmacology showed PT-141 produced rapid erections in men with erectile dysfunction, and a combination program with erectile blood-flow drugs began in 2024 [1]. But "early" is the key word — this evidence is investigational, not established, and not a green light. This page summarizes the male and erectile research honestly, marked off-label throughout, and recommends nothing.
Off-label means outside the approval
The distinction this page rests on is simple. Bremelanotide's approval (NDA 210557, June 2019) covers acquired, generalized HSDD in premenopausal women — and nothing else [3][6]. Any use in men is off-label: not prohibited as a clinical decision, but not supported by the approval and not backed by a completed Phase 3 program in men. The early-phase male evidence is genuine and worth summarizing, which is what follows — but it is described as investigational because that is what it is. Material sold as "PT-141 research chemical" compounds the issue: it is laboratory material outside the approved drug entirely, with no oversight of what is actually in the vial.
Is PT-141 approved for men?
No. The FDA approval covers only HSDD in premenopausal women [3][6]. Use in men for erectile dysfunction is off-label, and the supporting evidence is early-phase and investigational — early intranasal erectile-response data and a Phase 2 combination program begun in 2024 [1].
The investigational male and erectile evidence
The male erectile signal is, historically, where PT-141 began. The foundational pharmacology reported that systemic PT-141 produced dose-dependent erectile activity in rats and nonhuman primates and rapid, dose-dependent erectile responses in men with erectile dysfunction — with early intranasal dose-escalation studies describing a statistically significant erectile response above roughly 7 mg [1]. Development on the male side then lagged the female HSDD program, in part because the early intranasal route was discontinued due to pharmacokinetic variability [1]. More recently, a Phase 2 program studying bremelanotide in combination with a PDE-5 inhibitor (the centrally-acting melanocortin agonist paired with a peripheral blood-flow drug) was initiated in 2024 [1]. Reviews of emerging erectile-dysfunction therapies discuss melanocortin receptor agonists such as bremelanotide among investigational, centrally-acting approaches [11]. All of this is early-phase: a promising mechanistic rationale and preliminary data, not an approved or established male indication.
Why a central mechanism is plausible in men
The mechanistic case for studying PT-141 in men is the same one that underpins its approved use in women. It acts centrally on MC4R/MC3R in hypothalamic circuits of sexual motivation, not peripherally on vascular smooth muscle the way PDE-5 inhibitors do [1]. In principle that makes it a candidate for combination with blood-flow-based therapies — addressing desire centrally while another agent addresses erectile hemodynamics peripherally — which is the logic of the 2024 combination program [1]. Plausibility is not proof, though. The human male efficacy data remains early-phase, the historical record carries a disputed 2008 study flagged with a 2023 Expression of Concern [11], and the tolerability profile that applies in women — nausea-led, with a transient blood-pressure rise — would apply to men as well (see PT-141 side effects).